Al-Aidarous, Sayed;
Protonotarios, Alexandros;
Elliott, Perry M;
Lambiase, Pier D;
(2023)
Management of arrhythmogenic right ventricular cardiomyopathy.
Heart
10.1136/heartjnl-2023-322612.
(In press).
Preview |
Text
ARVC Heart Review - Reviewers Comments Included- track changes.pdf Download (491kB) | Preview |
![[thumbnail of Risk Score Figure.png]](https://discovery.ucl.ac.uk/10178948/3/Risk%20Score%20Figure.png)  Preview |
Image
Risk Score Figure.png Download (2MB) | Preview |
Abstract
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease characterised by fibrofatty replacement of the ventricular myocardium due to specific mutations, leading to ventricular arrhythmias and sudden cardiac death. Treating this condition can be challenging due to progressive fibrosis, phenotypic variations and small patient cohorts limiting the feasibility of conducting meaningful clinical trials. Although widely used, the evidence base for anti-arrhythmic drugs is limited. Beta-blockers are theoretically sound, yet their efficacy in reducing arrhythmic risk is not robust. Additionally, the impact of sotalol and amiodarone is inconsistent with studies reporting contradictory results. Emerging evidence suggests that combining flecainide and bisoprolol may be efficacious.Radiofrequency ablation has shown some potential in disrupting ventricular tachycardia circuits, with combined endo and epicardial ablation yielding better results which could be considered at the index procedure. In addition, stereotactic radiotherapy may be a future option that can decrease arrhythmias beyond simple scar formation by altering levels of Nav1.5 channels, Connexin 43 and Wnt signalling, potentially modifying myocardial fibrosis.Future therapies, such as adenoviruses and GSk3b modulation, are still in early-stage research. While implantable cardioverter-defibrillator implantation is a key intervention for reducing arrhythmic death, the risks of inappropriate shocks and device complications must be carefully considered.
| Type: | Article |
|---|---|
| Title: | Management of arrhythmogenic right ventricular cardiomyopathy |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1136/heartjnl-2023-322612 |
| Publisher version: | http://dx.doi.org/10.1136/heartjnl-2023-322612 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. |
| Keywords: | Arrhythmias, Cardiac, Arrhythmogenic Right Ventricular Dysplasia, Catheter Ablation, Defibrillators, Implantable, Tachycardia, Ventricular |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science > Clinical Science |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10178948 |
Archive Staff Only
 |
View Item |
